Exelixis Inc (EXEL)
34.50
+0.29
(+0.85%)
USD |
NASDAQ |
Jan 08, 16:00
34.52
+0.02
(+0.06%)
After-Hours: 20:00
Exelixis SG&A Expense (Quarterly): 111.80M for Sept. 30, 2024
SG&A Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (Quarterly) Benchmarks
| Merck & Co Inc | 2.731B |
| ADMA Biologics Inc | 18.56M |
| Alnylam Pharmaceuticals Inc | 220.99M |
| Incyte Corp | 309.20M |
| Sarepta Therapeutics Inc | 128.20M |